[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20211295A1 - Anticuerpos anti il-36 y procedimientos de uso de estos - Google Patents

Anticuerpos anti il-36 y procedimientos de uso de estos

Info

Publication number
PE20211295A1
PE20211295A1 PE2021000904A PE2021000904A PE20211295A1 PE 20211295 A1 PE20211295 A1 PE 20211295A1 PE 2021000904 A PE2021000904 A PE 2021000904A PE 2021000904 A PE2021000904 A PE 2021000904A PE 20211295 A1 PE20211295 A1 PE 20211295A1
Authority
PE
Peru
Prior art keywords
hvr
seq
sequence
amino acids
pustulosis
Prior art date
Application number
PE2021000904A
Other languages
English (en)
Inventor
Chingwei Vivian Lee
Germaine Fuh-Kelly
Louise Scharf
Tina Thai
Ashka Patel
Shashank Bharill
Erik Edward Karrer
Original Assignee
23Andme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 23Andme Inc filed Critical 23Andme Inc
Publication of PE20211295A1 publication Critical patent/PE20211295A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UN ANTICUERPO ANTI IL-36 QUE COMPRENDE: A) UNA HVR-L1 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 18; B) UNA HVR-L2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 19; C) UNA HVR-L3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 20; D) UNA HVR-H1 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 66, 82, 86, 90 O 252-283; E) UNA HVR-H2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 67, 83, 87, 91, 99, 103, 119 O 285-321; Y F) UNA HVR-H3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 68, 84, 88, 100, 104, 112, 120 O 323-335. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO, EL CUAL ES UTIL EN EL TRATAMIENTO DE ACNE E HIDRADENITIS SUPURATIVA (PASH), PUSTULOSIS EXANTEMATICA AGUDA GENERALIZADA (AGEP), PUSTULOSIS AMICROBIANA DE LOS PLIEGUES.
PE2021000904A 2018-12-21 2019-12-19 Anticuerpos anti il-36 y procedimientos de uso de estos PE20211295A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862784316P 2018-12-21 2018-12-21
PCT/US2019/067435 WO2020132220A1 (en) 2018-12-21 2019-12-19 Anti-il-36 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20211295A1 true PE20211295A1 (es) 2021-07-20

Family

ID=69187940

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000904A PE20211295A1 (es) 2018-12-21 2019-12-19 Anticuerpos anti il-36 y procedimientos de uso de estos

Country Status (19)

Country Link
US (2) US11884719B2 (es)
EP (1) EP3898673A1 (es)
JP (1) JP2022514950A (es)
KR (1) KR20210107721A (es)
CN (1) CN113454113A (es)
AR (1) AR123405A1 (es)
AU (1) AU2019405782A1 (es)
BR (1) BR112021010374A2 (es)
CA (1) CA3120474A1 (es)
CL (1) CL2021001615A1 (es)
CO (1) CO2021007882A2 (es)
EA (1) EA202191656A1 (es)
IL (1) IL283884A (es)
MX (1) MX2021007589A (es)
PE (1) PE20211295A1 (es)
SG (1) SG11202106100VA (es)
TW (1) TW202035460A (es)
WO (1) WO2020132220A1 (es)
ZA (1) ZA202103311B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017022086A2 (pt) 2015-04-15 2018-07-03 Anaptysbio Inc anticorpos dirigidos contra o receptor de interleucina 36 (il-36r)
WO2021259880A1 (en) * 2020-06-22 2021-12-30 Almirall, S.A. Anti-il-36 antibodies and methods of use thereof
WO2022150644A1 (en) * 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022150642A1 (en) * 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US5863769A (en) 1997-01-28 1999-01-26 Smithkline Beecham Corporation DNA encoding interleukin-1 receptor antagonist (IL-1raβ)
US6054559A (en) 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
EP1044271A1 (en) 1998-01-09 2000-10-18 Immunex Corporation Il-1 delta dna and polypeptides
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US20020192751A1 (en) 1998-05-15 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE69932247T2 (de) 1998-08-21 2007-05-31 Immunex Corp., Thousand Oaks Menschliches il-1 epsilon dna und polypeptide
US6838290B2 (en) 1998-08-21 2005-01-04 Immunex Corporation Methods for screening compounds that affect IL-1 epsilon activity
US6680380B1 (en) 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
JP5456222B2 (ja) 1998-12-23 2014-03-26 ジェネンテック， インコーポレイテッド Ｉｌ−１関連ポリペプチド
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK2270150T4 (da) 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US20020068279A1 (en) 1999-12-06 2002-06-06 Curagen Corporation Novel Proteins and nucleic acids encoding the same
MXPA02005729A (es) 1999-12-10 2002-09-18 Amgen Inc Moleculas tipo antagonista del receptor de inteleucina-1 y usos de las mismas.
US6843987B2 (en) 2000-02-02 2005-01-18 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030166069A1 (en) 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20030224984A1 (en) 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003034984A2 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003085096A2 (en) 2002-04-01 2003-10-16 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
WO2004028479A2 (en) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK2289936T3 (en) 2002-12-16 2017-07-31 Genentech Inc IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP2074139B1 (en) * 2006-09-08 2013-10-23 Amgen, Inc Il-1 family variants
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20100255012A1 (en) 2007-05-31 2010-10-07 Genmab A/S Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
JP5511654B2 (ja) 2007-05-31 2014-06-04 ゲンマブ エー／エス 分子操作により得られた組換え非グリコシル化一価半抗体
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
RU2011105466A (ru) * 2008-08-28 2012-10-10 ВАЙЕТ ЭлЭлСи (US) Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях
WO2012009704A2 (en) 2010-07-16 2012-01-19 Avantgen, Inc. Novel peptides and uses thereof
LT2644698T (lt) * 2010-11-17 2018-02-26 Chugai Seiyaku Kabushiki Kaisha Daugiaspecifinė antigeną surišanti molekulė, turinti alternatyvią funkciją kraujo krešėjimo viii faktoriaus funkcijai
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130102486A1 (en) 2011-10-20 2013-04-25 The Board Of Trustees Of The Leland Stanford Junior University Perp as a prognostic and diagnostic marker for dysplasia and cancer
JP6289375B2 (ja) * 2011-11-16 2018-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体
WO2015086830A1 (en) 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
CA2940585C (en) 2014-04-15 2023-08-08 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Differential diagnosis of eczema and psoriasis
WO2016042131A1 (en) 2014-09-18 2016-03-24 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
BR112017022086A2 (pt) * 2015-04-15 2018-07-03 Anaptysbio Inc anticorpos dirigidos contra o receptor de interleucina 36 (il-36r)
WO2016173605A1 (en) * 2015-04-29 2016-11-03 Institute For Research In Biomedicine Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
WO2017058944A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
MA43342A (fr) * 2015-09-30 2018-08-08 Medimmune Ltd Compositions et procédé d'inhibition de cellules souches cancéreuses
KR20180072820A (ko) * 2015-11-02 2018-06-29 얀센 파마슈티카 엔.브이. 항-il1rap 항체, il1rap 및 cd3과 결합하는 이중특이성 항원 결합 분자, 및 그의 용도
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
MX2019004448A (es) * 2016-10-21 2019-08-14 Adimab Llc Anticuerpos anti-virus respiratorio sincitial y metodos de generacion y uso de estos.
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
EP3401332A1 (en) * 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions

Also Published As

Publication number Publication date
US20240132582A1 (en) 2024-04-25
IL283884A (en) 2021-07-29
WO2020132220A1 (en) 2020-06-25
WO2020132220A9 (en) 2020-09-10
CO2021007882A2 (es) 2021-06-21
US11884719B2 (en) 2024-01-30
EA202191656A1 (ru) 2021-10-26
MX2021007589A (es) 2021-12-10
US20200199217A1 (en) 2020-06-25
SG11202106100VA (en) 2021-07-29
BR112021010374A2 (pt) 2021-08-24
ZA202103311B (en) 2022-10-26
CN113454113A (zh) 2021-09-28
AR123405A1 (es) 2022-11-30
AU2019405782A1 (en) 2021-06-17
KR20210107721A (ko) 2021-09-01
CA3120474A1 (en) 2020-06-25
EP3898673A1 (en) 2021-10-27
JP2022514950A (ja) 2022-02-16
CL2021001615A1 (es) 2021-11-26
TW202035460A (zh) 2020-10-01

Similar Documents

Publication Publication Date Title
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
PE20211295A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
PE20201186A1 (es) Anticuerpos antitau y metodos de uso
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
PE20210342A1 (es) Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
PE20120877A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
PE20141562A1 (es) Anticuerpos anti-htra1 y metodos de uso
PE20120878A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
AR091701A1 (es) Anticuerpos anti-cd22 e inmunoconjugados
PE20181402A1 (es) Anticuerpos anti-c5 y metodos de uso
PE20150945A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
PE20170935A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
PE20150211A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
PE20180317A1 (es) Anticuerpos anti-tau y metodos de uso
AR098743A1 (es) Anticuerpos e inmunoconjugados anti-cd33
AR114281A1 (es) Anticuerpos anti-klk5 y métodos de uso
PE20141693A1 (es) Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek
PE20201447A1 (es) Anticuerpos anti-componente de complemento y metodos de uso
PE20161376A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso
PE20142167A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados
PE20181009A1 (es) ANTICUERPOS ANTI-HtrA1 Y METODOS DE USO DE LOS MISMOS
NZ626520A (en) Anti-lrp5 antibodies and methods of use
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso